Abstract
The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Current Pharmaceutical Design
Title: Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective
Volume: 17 Issue: 7
Author(s): Richard G. Knowles
Affiliation:
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Abstract: The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Export Options
About this article
Cite this article as:
G. Knowles Richard, Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective, Current Pharmaceutical Design 2011; 17 (7) . https://dx.doi.org/10.2174/138161211795429019
DOI https://dx.doi.org/10.2174/138161211795429019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Tuberculosis, an Old Disease Lacking New Therapeutic Drugs
Current Drug Therapy Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Dexmedetomidine: A Review of its Use for the Management of Pain, Agitation, and Delirium in the Intensive Care Unit
Current Pharmaceutical Design Bridging Indigenous Knowledge and Scientific Evidence for Pharmacological Studies of <i>Phaleria macrocarpa</i>: A Systematic Review
The Natural Products Journal Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Manoyl-Oxide Biotransformations with Filamentous Fungi
Current Organic Chemistry Study of Anti-inflammatory Activity of a New Non-opioid Analgesic on the Basis of a Selective Inhibitor of TRPA1 Ion Channels
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry A Review on Common Ingredients of Periocular Cosmetics and Their Hazards
Current Organic Chemistry QSAR Study on 5-Lipoxygenase Activating Protein (FLAP) Inhibitors: The Derivatives of 2,2-Bisaryl-Bicycloheptane
Letters in Drug Design & Discovery Efficacy and Safety of Inhaled and Intranasal Corticosteroids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued)